Method for reducing effect of hematocrit on measurement of an analyte in whole blood, and test kit and test article useful in the method
CA 2457665 C · Owner: Ascensia Diabetes Care Holdings Ag · Inventors: Marfurt, Karen L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method for determining the presence and/or amount of an analyte in a sample of whole blood comprises the step of treating the sample with a nonlytic hypertonic salt compo- sition to reduce the hematocrit by reducing the size of the red blood cells. In optical detection systems the smaller red blood cells create greater scatter which allows a more accurate cor- rection to be applied in a dual-wavelength detection system. In electrochemical detection systems as well as in optical detection systems the smaller red blood cells provide less ob- struction to the diffusion of analyte and reagents in the sample to facilitate the reactions thereof.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 10, 2004 and granted December 18, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 10, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 10, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.